デフォルト表紙
市場調査レポート
商品コード
1193077

セルライト治療市場:施術タイプ別、セルライトタイプ別、エンドユーザー別:世界の機会分析および産業予測、2021-2031年

Cellulite Treatment Market By Procedure Type, By Cellulite Type, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031

出版日: | 発行: Allied Market Research | ページ情報: 英文 290 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
セルライト治療市場:施術タイプ別、セルライトタイプ別、エンドユーザー別:世界の機会分析および産業予測、2021-2031年
出版日: 2022年10月01日
発行: Allied Market Research
ページ情報: 英文 290 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のセルライト治療市場は、2021年に21億4000万米ドル、2031年には57億2906万米ドルに達すると予測され、2022年から2031年までのCAGRは10.3%を記録しています。

セルライトは、繊維性結合組織内の皮下脂肪のヘルニアで、皮膚のくぼみや結節として現れ、骨盤部(特に臀部)、下肢、腹部などに多くみられます。この症状は女性に多く見られます。

ファーストフードの消費と座りがちなライフスタイルによる肥満の増加が、市場の成長を牽引しています。体重増加や高脂肪は、セルライトの発生に関与しています。また、美容施術の増加や美容クリニックの増加も、市場の成長に寄与しています。例えば、国際美容整形外科学会(ISAPS)の調査によると、2020年には世界で約10,129,528件の美容外科手術が実施されています。ソーシャルメディアの影響や若い世代に人気のある有名人のおかげで、男性も女性も魅力的な外見への需要が高まり、美的に魅力的に見えるように動機付けられ、市場成長のための十分な機会を提供しています。セルライト治療は、特に太ももやお尻の周りから脂肪の沈着を減少させ、さらに外観を向上させます。

低侵襲な美容整形手術の需要の増加、美容整形手術の人気の上昇、主に女性における遺伝的要因は、市場成長に向けて貢献しています。高度な非侵襲的セルライト治療に関する認知度の向上、美容外科医の数の急増は、今後数年間で市場の成長を促進すると予想されます。

さらに、主要プレイヤーによる先進的なセルライト治療の開発、製品承認、市場における新規製品発売のための研究開発活動の増加が、市場成長を後押しします。例えば、2020年7月、高度に焦点を当てた専門ブランドおよびジェネリック医薬品会社であるEndo International plcは、その、成人女性の臀部の中程度から重度のセルライトの治療のためのQwo(コラゲナーゼクロストリジウムヒストリクム-aaes)について米国食品医薬品局(FDA)の承認を取得しました。しかし、先進的なセルライト治療には高い費用がかかり、新興国では医療インフラが未発達であることから、市場成長の妨げになる可能性があります。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資ポケット
  • ポーターのファイブフォース分析
  • 主要企業のポジショニング
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • COVID-19 影響分析

第4章 セルライト治療市場:治療法タイプ別

  • 概要
    • 市場規模および予測
  • 非侵襲性
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別
  • 低侵襲
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別
  • 局所麻酔
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別

第5章 セルライト治療市場:セルライトタイプ別

  • 概要
    • 市場規模および予測
  • 軟質セルライト
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別
    • 軟質セルライト・セルライト治療市場: 性別
      • 男性市場規模・予測:地域別
      • 女性市場規模・予測:地域別
  • 硬質セルライト
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析: 国別
    • 硬質セルライトのセルライト治療市場: 性別
      • 男性市場規模・予測:地域別
      • 女性市場規模推移・予測:地域別
  • 浮腫性
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別

第6章 セルライト治療市場:エンドユーザー別

  • 概要
    • 市場規模・予測
  • 病院
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別
  • クリニック、ビューティーセンター
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別
  • その他
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別

第7章 セルライト治療薬市場:地域別

  • 概要
    • 市場規模・予測
  • 北米
    • 主な動向と機会
    • 北米市場規模・予測:施術タイプ別
    • 北米の市場規模・予測:セルライトタイプ別
      • 北米の軟質セルライト・セルライト治療市場:性別
      • 北米の硬質セルライト・セルライト治療市場:性別
    • 北米の市場規模・予測:エンドユーザー別
    • 北米市場規模・予測:国別
      • 米国
      • カナダ
      • メキシコ
  • 欧州
    • 主要動向と機会
    • 欧州市場規模・予測:施術タイプ別
    • 欧州の市場規模・予測:セルライトタイプ別
      • 欧州の軟質セルライト・セルライト治療市場:性別
      • 欧州硬質セルライト・セルライト治療市場:性別
    • 欧州市場規模・予測:エンドユーザー別
    • 欧州市場規模・予測:国別
      • ドイツ
      • フランス
      • 英国
      • イタリア
      • スペイン
      • その他の欧州地域
  • アジア太平洋地域
    • 主な動向と機会
    • アジア太平洋地域の市場規模・予測:施術タイプ別
    • アジア太平洋地域の市場規模・予測:セルライトタイプ別
      • アジア太平洋地域の軟質セルライト・セルライト治療市場:男女別
      • アジア太平洋地域の硬質セルライト・セルライト治療市場:男女別
    • アジア太平洋地域の市場規模・予測:エンドユーザー別
    • アジア太平洋地域の市場規模・予測:国別
      • 日本
      • 中国
      • オーストラリア
      • インド
      • その他アジア太平洋地域
  • LAMEA
    • 主な動向と機会
    • LAMEAの市場規模・予測:施術タイプ別
    • LAMEAの市場規模・予測:セルライトタイプ別
      • LAMEAの軟質セルライト・セルライト治療市場:男女別
      • LAMEAの硬質セルライト・セルライト治療市場:男女別
    • LAMEAの市場規模・予測:エンドユーザー別
    • LAMEAの市場規模・予測:国別
      • ブラジル
      • サウジアラビア
      • 南アフリカ
      • LAMEAの残りの地域

第8章 企業情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合のヒートマップ
  • 主な発展

第9章 企業プロファイル

  • Abbvie Inc
  • Candela Syneron
  • Cynosure Technologies
  • Merz Pharma GmbH & Co. KGaA
  • Bausch Health Companies Inc.
  • Hologic Inc
  • Zimmer Aesthetics
  • Galderma SA
  • Sinclair Pharmaceuticals Limited
  • Endo International plc
図表

LIST OF TABLES

  • TABLE 1. GLOBAL CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 2. CELLULITE TREATMENT MARKET, FOR NON-INVASIVE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. CELLULITE TREATMENT MARKET FOR NON-INVASIVE, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. CELLULITE TREATMENT MARKET, FOR MINIMALLY INVASIVE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. CELLULITE TREATMENT MARKET FOR MINIMALLY INVASIVE, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. CELLULITE TREATMENT MARKET, FOR TOPICAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 7. CELLULITE TREATMENT MARKET FOR TOPICAL, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 8. GLOBAL CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 9. CELLULITE TREATMENT MARKET, FOR SOFT CELLULITE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. CELLULITE TREATMENT MARKET FOR SOFT CELLULITE, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 11. GLOBAL SOFT CELLULITE CELLULITE TREATMENT MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 12. CELLULITE TREATMENT MARKET, FOR MALE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. CELLULITE TREATMENT MARKET, FOR FEMALE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. CELLULITE TREATMENT MARKET, FOR HARD CELLULITE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 15. CELLULITE TREATMENT MARKET FOR HARD CELLULITE, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 16. GLOBAL HARD CELLULITE CELLULITE TREATMENT MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 17. CELLULITE TREATMENT MARKET, FOR MALE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 18. CELLULITE TREATMENT MARKET, FOR FEMALE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 19. CELLULITE TREATMENT MARKET, FOR EDEMATOUS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 20. CELLULITE TREATMENT MARKET FOR EDEMATOUS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 21. GLOBAL CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 22. CELLULITE TREATMENT MARKET, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 23. CELLULITE TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 24. CELLULITE TREATMENT MARKET, FOR CLINICS AND BEAUTY CENTERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 25. CELLULITE TREATMENT MARKET FOR CLINICS AND BEAUTY CENTERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 26. CELLULITE TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 27. CELLULITE TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 28. CELLULITE TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 29. NORTH AMERICA CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 30. NORTH AMERICA CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 31. NORTH AMERICA SOFT CELLULITE CELLULITE TREATMENT MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 32. NORTH AMERICA HARD CELLULITE CELLULITE TREATMENT MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 33. NORTH AMERICA CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 34. NORTH AMERICA CELLULITE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 35. U.S. CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 36. U.S. CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 37. U.S. CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 38. CANADA CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 39. CANADA CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 40. CANADA CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 41. MEXICO CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 42. MEXICO CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 43. MEXICO CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 44. EUROPE CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 45. EUROPE CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 46. EUROPE SOFT CELLULITE CELLULITE TREATMENT MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 47. EUROPE HARD CELLULITE CELLULITE TREATMENT MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 48. EUROPE CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 49. EUROPE CELLULITE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 50. GERMANY CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 51. GERMANY CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 52. GERMANY CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 53. FRANCE CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 54. FRANCE CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 55. FRANCE CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 56. UK CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 57. UK CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 58. UK CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 59. ITALY CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 60. ITALY CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 61. ITALY CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 62. SPAIN CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 63. SPAIN CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 64. SPAIN CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 65. REST OF EUROPE CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 66. REST OF EUROPE CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 67. REST OF EUROPE CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 68. ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 69. ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 70. ASIA-PACIFIC SOFT CELLULITE CELLULITE TREATMENT MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 71. ASIA-PACIFIC HARD CELLULITE CELLULITE TREATMENT MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 72. ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 73. ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 74. JAPAN CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 75. JAPAN CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 76. JAPAN CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 77. CHINA CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 78. CHINA CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 79. CHINA CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 80. AUSTRALIA CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 81. AUSTRALIA CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 82. AUSTRALIA CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 83. INDIA CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 84. INDIA CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 85. INDIA CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 86. REST OF ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 87. REST OF ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 88. REST OF ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 89. LAMEA CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 90. LAMEA CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 91. LAMEA SOFT CELLULITE CELLULITE TREATMENT MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 92. LAMEA HARD CELLULITE CELLULITE TREATMENT MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 93. LAMEA CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 94. LAMEA CELLULITE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 95. BRAZIL CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 96. BRAZIL CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 97. BRAZIL CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 98. SAUDI ARABIA CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 99. SAUDI ARABIA CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 100. SAUDI ARABIA CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 101. SOUTH AFRICA CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 102. SOUTH AFRICA CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 103. SOUTH AFRICA CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 104. REST OF LAMEA CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 105. REST OF LAMEA CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 106. REST OF LAMEA CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 107.ABBVIE INC: COMPANY SNAPSHOT
  • TABLE 108.ABBVIE INC: OPERATING SEGMENTS
  • TABLE 109.ABBVIE INC: PRODUCT PORTFOLIO
  • TABLE 110.ABBVIE INC: NET SALES,
  • TABLE 111.ABBVIE INC: KEY STRATERGIES
  • TABLE 112.CANDELA SYNERON: COMPANY SNAPSHOT
  • TABLE 113.CANDELA SYNERON: OPERATING SEGMENTS
  • TABLE 114.CANDELA SYNERON: PRODUCT PORTFOLIO
  • TABLE 115.CANDELA SYNERON: NET SALES,
  • TABLE 116.CANDELA SYNERON: KEY STRATERGIES
  • TABLE 117.CYNOSURE TECHNOLOGIES: COMPANY SNAPSHOT
  • TABLE 118.CYNOSURE TECHNOLOGIES: OPERATING SEGMENTS
  • TABLE 119.CYNOSURE TECHNOLOGIES: PRODUCT PORTFOLIO
  • TABLE 120.CYNOSURE TECHNOLOGIES: NET SALES,
  • TABLE 121.CYNOSURE TECHNOLOGIES: KEY STRATERGIES
  • TABLE 122.MERZ PHARMA GMBH & CO. KGAA: COMPANY SNAPSHOT
  • TABLE 123.MERZ PHARMA GMBH & CO. KGAA: OPERATING SEGMENTS
  • TABLE 124.MERZ PHARMA GMBH & CO. KGAA: PRODUCT PORTFOLIO
  • TABLE 125.MERZ PHARMA GMBH & CO. KGAA: NET SALES,
  • TABLE 126.MERZ PHARMA GMBH & CO. KGAA: KEY STRATERGIES
  • TABLE 127.BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
  • TABLE 128.BAUSCH HEALTH COMPANIES INC.: OPERATING SEGMENTS
  • TABLE 129.BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
  • TABLE 130.BAUSCH HEALTH COMPANIES INC.: NET SALES,
  • TABLE 131.BAUSCH HEALTH COMPANIES INC.: KEY STRATERGIES
  • TABLE 132.HOLOGIC INC: COMPANY SNAPSHOT
  • TABLE 133.HOLOGIC INC: OPERATING SEGMENTS
  • TABLE 134.HOLOGIC INC: PRODUCT PORTFOLIO
  • TABLE 135.HOLOGIC INC: NET SALES,
  • TABLE 136.HOLOGIC INC: KEY STRATERGIES
  • TABLE 137.ZIMMER AESTHETICS: COMPANY SNAPSHOT
  • TABLE 138.ZIMMER AESTHETICS: OPERATING SEGMENTS
  • TABLE 139.ZIMMER AESTHETICS: PRODUCT PORTFOLIO
  • TABLE 140.ZIMMER AESTHETICS: NET SALES,
  • TABLE 141.ZIMMER AESTHETICS: KEY STRATERGIES
  • TABLE 142.GALDERMA SA: COMPANY SNAPSHOT
  • TABLE 143.GALDERMA SA: OPERATING SEGMENTS
  • TABLE 144.GALDERMA SA: PRODUCT PORTFOLIO
  • TABLE 145.GALDERMA SA: NET SALES,
  • TABLE 146.GALDERMA SA: KEY STRATERGIES
  • TABLE 147.SINCLAIR PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
  • TABLE 148.SINCLAIR PHARMACEUTICALS LIMITED: OPERATING SEGMENTS
  • TABLE 149.SINCLAIR PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
  • TABLE 150.SINCLAIR PHARMACEUTICALS LIMITED: NET SALES,
  • TABLE 151.SINCLAIR PHARMACEUTICALS LIMITED: KEY STRATERGIES
  • TABLE 152.ENDO INTERNATIONAL PLC: COMPANY SNAPSHOT
  • TABLE 153.ENDO INTERNATIONAL PLC: OPERATING SEGMENTS
  • TABLE 154.ENDO INTERNATIONAL PLC: PRODUCT PORTFOLIO
  • TABLE 155.ENDO INTERNATIONAL PLC: NET SALES,
  • TABLE 156.ENDO INTERNATIONAL PLC: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.CELLULITE TREATMENT MARKET SEGMENTATION
  • FIGURE 2.CELLULITE TREATMENT MARKET,2021-2031
  • FIGURE 3.CELLULITE TREATMENT MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.CELLULITE TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.CELLULITE TREATMENT MARKET,BY PROCEDURE TYPE,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF NON-INVASIVE CELLULITE TREATMENT MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF MINIMALLY INVASIVE CELLULITE TREATMENT MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF TOPICAL CELLULITE TREATMENT MARKET,2021-2031(%)
  • FIGURE 16.CELLULITE TREATMENT MARKET,BY CELLULITE TYPE,2021(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF SOFT CELLULITE CELLULITE TREATMENT MARKET,2021-2031(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF HARD CELLULITE CELLULITE TREATMENT MARKET,2021-2031(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF EDEMATOUS CELLULITE TREATMENT MARKET,2021-2031(%)
  • FIGURE 20.CELLULITE TREATMENT MARKET,BY END USER,2021(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF HOSPITALS CELLULITE TREATMENT MARKET,2021-2031(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF CLINICS AND BEAUTY CENTERS CELLULITE TREATMENT MARKET,2021-2031(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF OTHERS CELLULITE TREATMENT MARKET,2021-2031(%)
  • FIGURE 24.CELLULITE TREATMENT MARKET BY REGION,2021
  • FIGURE 25.U.S. CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 26.CANADA CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 27.MEXICO CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 28.GERMANY CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 29.FRANCE CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 30.UK CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 31.ITALY CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 32.SPAIN CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 33.REST OF EUROPE CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 34.JAPAN CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 35.CHINA CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 36.AUSTRALIA CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 37.INDIA CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 38.REST OF ASIA-PACIFIC CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 39.BRAZIL CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 40.SAUDI ARABIA CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 41.SOUTH AFRICA CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 42.REST OF LAMEA CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 46.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 47.COMPETITIVE DASHBOARD
  • FIGURE 48.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 49.ABBVIE INC.: NET SALES ,($MILLION)
  • FIGURE 50.CANDELA SYNERON.: NET SALES ,($MILLION)
  • FIGURE 51.CYNOSURE TECHNOLOGIES.: NET SALES ,($MILLION)
  • FIGURE 52.MERZ PHARMA GMBH & CO. KGAA.: NET SALES ,($MILLION)
  • FIGURE 53.BAUSCH HEALTH COMPANIES INC..: NET SALES ,($MILLION)
  • FIGURE 54.HOLOGIC INC.: NET SALES ,($MILLION)
  • FIGURE 55.ZIMMER AESTHETICS.: NET SALES ,($MILLION)
  • FIGURE 56.GALDERMA SA.: NET SALES ,($MILLION)
  • FIGURE 57.SINCLAIR PHARMACEUTICALS LIMITED.: NET SALES ,($MILLION)
  • FIGURE 58.ENDO INTERNATIONAL PLC.: NET SALES ,($MILLION)
目次
Product Code: A10923

The global cellulite treatment market was valued at $2,140.0 million in 2021, and is projected to reach $5,729.06 million by 2031, registering a CAGR of 10.3% from 2022 to 2031.

Cellulite is the herniation of subcutaneous fat within fibrous connective tissue that manifests as skin dimpling and nodularity, often on the pelvic region (specifically the buttocks), lower limbs, and abdomen. The condition is most prevalent in women.

The increase in obesity rate owing to fast food consumption and sedentary lifestyle drive the growth of the market. Weight gain and high obesity are responsible for the development of cellulites. In addition, the increase in the number of cosmetic procedures and the rise in a number of cosmetic clinics contribute toward the growth of the market. For instance, according to International Society of Aesthetic Plastic Surgery (ISAPS) survey, in 2020 about 10,129,528 cosmetic surgical procedures are carried worldwide. The rise in demand for attractive physical appearance in men and women owing to social media influence and celebrities who are popular among the young generation, motivate them to look aesthetically appealing, which provides ample opportunities for market growth. The cellulite treatment, reduces the fat depositions especially from around the thighs and buttocks which further enhances the appearance.

The increase in demand for minimally invasive cosmetic procedures, rise in popularity of cosmetic procedures and genetical factors predominantly in women contribute toward the market growth. Increase in awareness about advanced non-invasive cellulite treatment, and surge in number of cosmetology surgeons are expected to drive the market growth in the coming years.

Moreover, the increase in R&D activities for development of advanced cellulite treatment, product approvals and novel product launch in the market by key players boost the market growth. For instance, in July 2020, Endo International plc, a highly-focused specialty branded and generics pharmaceutical company, has received U.S. Food and Drug Administration (FDA) approval for its, Qwo (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women. However, the high cost of advanced cellulite treatment and underdeveloped health care infrastructure in developing countries may hinder the growth of the market.

The cellulite treatment market is segmented on the basis of procedure type, cellulite type, end user and region. By procedure type, the market is divided into non-invasive, minimal invasive and topical. By cellulite type, the market is classified into soft cellulite, hard cellulite, and edematous cellulite. The soft cellulite segment is further divided into male and female. The hard cellulite segment is further bifurcated into male and female. By end user, the market is categorized into hospitals, clinics & beauty centers, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include ABBVIE, Bausch Health Companies Inc, Candela Syneron, Cynosure, Galderma SA, Johnson & Johnson, Merz Pharma GmbH & Co. KGaA, Sientra Inc, Sinclair Pharma and Teoxane Laboratories.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cellulite treatment market analysis from 2021 to 2031 to identify the prevailing cellulite treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the cellulite treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global cellulite treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Procedure Type

  • Non-invasive
  • Minimally Invasive
  • Topical

By Cellulite Type

  • Soft Cellulite
    • Gender
    • Male
    • Female
  • Hard Cellulite
    • Gender
    • Male
    • Female
  • Edematous

By End User

  • Hospitals
  • Clinics and Beauty Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • Rest Of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest Of LAMEA
  • Key Market Players
    • Abbvie Inc
    • Candela Syneron
    • Cynosure Technologies
    • Merz Pharma GmbH & Co. KGaA
    • Bausch Health Companies Inc.
    • Hologic Inc
    • Zimmer Aesthetics
    • Galderma SA
    • Sinclair Pharmaceuticals Limited
    • Endo International plc

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Non-invasive
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Minimally Invasive
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Topical
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country

CHAPTER 5: CELLULITE TREATMENT MARKET, BY CELLULITE TYPE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Soft Cellulite
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
    • 5.2.4 Soft Cellulite Cellulite Treatment Market by Gender
      • 5.2.4.1 Male Market size and forecast, by region
      • 5.2.4.2 Female Market size and forecast, by region
  • 5.3 Hard Cellulite
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
    • 5.3.4 Hard Cellulite Cellulite Treatment Market by Gender
      • 5.3.4.1 Male Market size and forecast, by region
      • 5.3.4.2 Female Market size and forecast, by region
  • 5.4 Edematous
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country

CHAPTER 6: CELLULITE TREATMENT MARKET, BY END USER

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospitals
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Clinics and Beauty Centers
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Others
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: CELLULITE TREATMENT MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Procedure Type
    • 7.2.3 North America Market size and forecast, by Cellulite Type
      • 7.2.3.1 North America Soft Cellulite Cellulite Treatment Market by Gender
      • 7.2.3.2 North America Hard Cellulite Cellulite Treatment Market by Gender
    • 7.2.4 North America Market size and forecast, by End User
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Procedure Type
      • 7.2.5.1.2 Market size and forecast, by Cellulite Type
      • 7.2.5.1.3 Market size and forecast, by End User
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Procedure Type
      • 7.2.5.2.2 Market size and forecast, by Cellulite Type
      • 7.2.5.2.3 Market size and forecast, by End User
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Procedure Type
      • 7.2.5.3.2 Market size and forecast, by Cellulite Type
      • 7.2.5.3.3 Market size and forecast, by End User
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Procedure Type
    • 7.3.3 Europe Market size and forecast, by Cellulite Type
      • 7.3.3.1 Europe Soft Cellulite Cellulite Treatment Market by Gender
      • 7.3.3.2 Europe Hard Cellulite Cellulite Treatment Market by Gender
    • 7.3.4 Europe Market size and forecast, by End User
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Procedure Type
      • 7.3.5.1.2 Market size and forecast, by Cellulite Type
      • 7.3.5.1.3 Market size and forecast, by End User
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Procedure Type
      • 7.3.5.2.2 Market size and forecast, by Cellulite Type
      • 7.3.5.2.3 Market size and forecast, by End User
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Procedure Type
      • 7.3.5.3.2 Market size and forecast, by Cellulite Type
      • 7.3.5.3.3 Market size and forecast, by End User
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Procedure Type
      • 7.3.5.4.2 Market size and forecast, by Cellulite Type
      • 7.3.5.4.3 Market size and forecast, by End User
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Procedure Type
      • 7.3.5.5.2 Market size and forecast, by Cellulite Type
      • 7.3.5.5.3 Market size and forecast, by End User
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Procedure Type
      • 7.3.5.6.2 Market size and forecast, by Cellulite Type
      • 7.3.5.6.3 Market size and forecast, by End User
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Procedure Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Cellulite Type
      • 7.4.3.1 Asia-Pacific Soft Cellulite Cellulite Treatment Market by Gender
      • 7.4.3.2 Asia-Pacific Hard Cellulite Cellulite Treatment Market by Gender
    • 7.4.4 Asia-Pacific Market size and forecast, by End User
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Procedure Type
      • 7.4.5.1.2 Market size and forecast, by Cellulite Type
      • 7.4.5.1.3 Market size and forecast, by End User
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Procedure Type
      • 7.4.5.2.2 Market size and forecast, by Cellulite Type
      • 7.4.5.2.3 Market size and forecast, by End User
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Market size and forecast, by Procedure Type
      • 7.4.5.3.2 Market size and forecast, by Cellulite Type
      • 7.4.5.3.3 Market size and forecast, by End User
      • 7.4.5.4 India
      • 7.4.5.4.1 Market size and forecast, by Procedure Type
      • 7.4.5.4.2 Market size and forecast, by Cellulite Type
      • 7.4.5.4.3 Market size and forecast, by End User
      • 7.4.5.5 Rest of Asia-Pacific
      • 7.4.5.5.1 Market size and forecast, by Procedure Type
      • 7.4.5.5.2 Market size and forecast, by Cellulite Type
      • 7.4.5.5.3 Market size and forecast, by End User
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Procedure Type
    • 7.5.3 LAMEA Market size and forecast, by Cellulite Type
      • 7.5.3.1 LAMEA Soft Cellulite Cellulite Treatment Market by Gender
      • 7.5.3.2 LAMEA Hard Cellulite Cellulite Treatment Market by Gender
    • 7.5.4 LAMEA Market size and forecast, by End User
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Procedure Type
      • 7.5.5.1.2 Market size and forecast, by Cellulite Type
      • 7.5.5.1.3 Market size and forecast, by End User
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Procedure Type
      • 7.5.5.2.2 Market size and forecast, by Cellulite Type
      • 7.5.5.2.3 Market size and forecast, by End User
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Procedure Type
      • 7.5.5.3.2 Market size and forecast, by Cellulite Type
      • 7.5.5.3.3 Market size and forecast, by End User
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Procedure Type
      • 7.5.5.4.2 Market size and forecast, by Cellulite Type
      • 7.5.5.4.3 Market size and forecast, by End User

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Abbvie Inc
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Candela Syneron
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Cynosure Technologies
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Merz Pharma GmbH & Co. KGaA
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Bausch Health Companies Inc.
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Hologic Inc
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Zimmer Aesthetics
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Galderma SA
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Sinclair Pharmaceuticals Limited
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Endo International plc
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments